189 related articles for article (PubMed ID: 11700580)
1. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
Zachary KC; Hanna GJ; D'Aquila RT
Clin Infect Dis; 2001 Dec; 33(12):2075-7. PubMed ID: 11700580
[TBL] [Abstract][Full Text] [Related]
2. HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
Murphy MD; Marousek GI; Chou S
J Clin Virol; 2004 May; 30(1):62-7. PubMed ID: 15072756
[TBL] [Abstract][Full Text] [Related]
3. Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation.
Lam E; Parkin NT
Clin Infect Dis; 2003 Nov; 37(9):1273-4. PubMed ID: 14557976
[No Abstract] [Full Text] [Related]
4. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
[TBL] [Abstract][Full Text] [Related]
5. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
Côté HC; Brumme ZL; Harrigan PR
J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
[TBL] [Abstract][Full Text] [Related]
7. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.
Ziermann R; Limoli K; Das K; Arnold E; Petropoulos CJ; Parkin NT
J Virol; 2000 May; 74(9):4414-9. PubMed ID: 10756056
[TBL] [Abstract][Full Text] [Related]
8. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.
Resch W; Ziermann R; Parkin N; Gamarnik A; Swanstrom R
J Virol; 2002 Sep; 76(17):8659-66. PubMed ID: 12163585
[TBL] [Abstract][Full Text] [Related]
9. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
Condra JH; Petropoulos CJ; Ziermann R; Schleif WA; Shivaprakash M; Emini EA
J Infect Dis; 2000 Sep; 182(3):758-65. PubMed ID: 10950769
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.
Martinez-Picado J; Wrin T; Frost SD; Clotet B; Ruiz L; Brown AJ; Petropoulos CJ; Parkin NT
J Virol; 2005 May; 79(10):5907-13. PubMed ID: 15857976
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
Torti C; Quiros-Roldan E; Monno L; Patroni A; Saracino A; Angarano G; Tinelli C; Lo Caputo S; Tirelli V; Mazzotta F; Carosi G; ;
J Med Virol; 2004 Sep; 74(1):29-33. PubMed ID: 15258965
[TBL] [Abstract][Full Text] [Related]
13. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Marcelin AG; Affolabi D; Lamotte C; Mohand HA; Delaugerre C; Wirden M; Voujon D; Bossi P; Ktorza N; Bricaire F; Costagliola D; Katlama C; Peytavin G; Calvez V
J Med Virol; 2004 Sep; 74(1):16-20. PubMed ID: 15258963
[TBL] [Abstract][Full Text] [Related]
14. Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
Cunyat F; Ruiz L; Marfil S; Puig T; Bofill M; Blanco J; Clotet B; Cabrera C
Antivir Ther; 2010; 15(3):431-6. PubMed ID: 20516562
[TBL] [Abstract][Full Text] [Related]
15. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
Doualla-Bell F; Avalos A; Gaolathe T; Mine M; Gaseitsiwe S; Ndwapi N; Novitsky VA; Brenner B; Oliveira M; Moisi D; Moffat H; Thior I; Essex M; Wainberg MA
Antimicrob Agents Chemother; 2006 Jun; 50(6):2210-3. PubMed ID: 16723586
[TBL] [Abstract][Full Text] [Related]
16. Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir.
Lastere S; Dalban C; Collin G; Descamps D; Girard PM; Clavel F; Costagliola D; Brun-Vezinet F;
Antivir Ther; 2004 Apr; 9(2):221-7. PubMed ID: 15134184
[TBL] [Abstract][Full Text] [Related]
17. [Resistance to protease inhibitors].
Clotet B; Martínez-Picado J; Arrizabalaga J; Ruiz L
Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):34-41. PubMed ID: 11428058
[No Abstract] [Full Text] [Related]
18. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
[TBL] [Abstract][Full Text] [Related]
19. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
Masquelier B; Assoumou KL; Descamps D; Bocket L; Cottalorda J; Ruffault A; Marcelin AG; Morand-Joubert L; Tamalet C; Charpentier C; Peytavin G; Antoun Z; Brun-Vézinet F; Costagliola D;
J Antimicrob Chemother; 2008 Jun; 61(6):1362-8. PubMed ID: 18390885
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus. Protease uninhibited.
Richman DD
Nature; 1995 Apr; 374(6522):494. PubMed ID: 7700370
[No Abstract] [Full Text] [Related]
[Next] [New Search]
